RECENT DEVELOPMENTS IN INSULIN DELIVERY TECHNIQUES - CURRENT STATUS AND FUTURE POTENTIAL

被引:58
作者
KENNEDY, FP [1 ]
机构
[1] MAYO CLIN & MAYO FDN, DEPT ENDOCRINOL & INTERNAL MED, ROCHESTER, MN 55905 USA
关键词
D O I
10.2165/00003495-199142020-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although single or multiple daily subcutaneous injections of insulin are the mainstay of insulin delivery techniques, several other methods of insulin delivery are now available or in development, including: (a) continuous subcutaneous insulin infusion by a wearable infusion pump; (b) total or segmental transplantation of a pancreas; (c) transplantation of isolated islet cells; (d) implantation of a programmable insulin pump; (e) oral, nasal, rectal and transdermal mechanisms of insulin delivery; (f) insulin analogues; (g) implantation of polymeric capsules which give continuous or time-pulsed release of insulin; and (h) implantation of a biohybrid artificial pancreas which uses encapsulated islets. Many of these methods of insulin delivery are aimed at achieving a more physiological means of delivery of the insulin, thus to improve glycaemic control and hopefully minimise the secondary complications of diabetes. Techniques of multiple insulin injections and continuous subcutaneous insulin infusion pumps are already in widespread use and are resulting in improved glycaemic control. With the recent increased use of pancreatic transplantation, the rule of establishing euglycaemia will be elucidated in the treatment and prevention of microvascular and macrovascular complications of diabetes mellitus. Despite these advances, the ideal delivery of insulin to patients has yet to be developed. Subcutaneous methods of insulin delivery do not precisely mimic physiological insulin needs and transplantation requires risky immunosuppression. However, the future does look bright as glucose sensors are developed and insulin analogues synthesised.
引用
收藏
页码:213 / 227
页数:15
相关论文
共 203 条
[1]   UNANTICIPATED AMYLOIDOSIS IN DOGS INFUSED WITH INSULIN [J].
ALBISSER, AM ;
MCADAM, KPWJ ;
PERLMAN, K ;
CARSON, S ;
BAHORIC, A ;
WILLIAMSON, JR .
DIABETES, 1983, 32 (12) :1092-1101
[2]   ARTIFICIAL ENDOCRINE PANCREAS [J].
ALBISSER, AM ;
LEIBEL, BS ;
EWART, TG ;
DAVIDOVAC, Z ;
BOTZ, CK ;
ZINGG, W .
DIABETES, 1974, 23 (05) :389-396
[3]   CLINICAL CONTROL OF DIABETES BY ARTIFICIAL PANCREAS [J].
ALBISSER, AM ;
LEIBEL, BS ;
EWART, TG ;
DAVIDOVAC, Z ;
BOTZ, CK ;
ZINGG, W ;
SCHIPPER, H ;
GANDER, R .
DIABETES, 1974, 23 (05) :397-404
[4]  
ALTMAN JJ, 1986, T AM SOC ART INT ORG, V32, P145
[5]   DEFECTIVE GLUCOSE COUNTERREGULATION AFTER STRICT GLYCEMIC CONTROL OF INSULIN-DEPENDENT DIABETES-MELLITUS [J].
AMIEL, SA ;
TAMBORLANE, WV ;
SIMONSON, DC ;
SHERWIN, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (22) :1376-1383
[6]   EFFECT OF INTENSIVE INSULIN THERAPY ON GLYCEMIC THRESHOLDS FOR COUNTERREGULATORY HORMONE-RELEASE [J].
AMIEL, SA ;
SHERWIN, RS ;
SIMONSON, DC ;
TAMBORLANE, WV .
DIABETES, 1988, 37 (07) :901-907
[7]   ORALLY-ADMINISTERED LIPOSOME-ENTRAPPED INSULIN IN DIABETIC ANIMALS - A CRITICAL-ASSESSMENT [J].
ARRIETAMOLERO, JF ;
ALECK, K ;
SINHA, MK ;
BROWNSCHEIDLE, CM ;
SHAPIRO, LJ ;
SPERLING, MA .
HORMONE RESEARCH, 1982, 16 (04) :249-256
[8]  
AUNGST BJ, 1988, J PHARMACOL EXP THER, V244, P23
[9]  
BAK JF, 1987, DIABETES RES CLIN EX, V6, P155
[10]  
BENDING JJ, 1985, DIABETOLOGIA, V28, P113